Form 4: Heidi Henson, Director at Perspective Therapeutics, Acquires 50,000 Stock Options

Director Heidi Henson acquired 50,000 stock options in Perspective Therapeutics, Inc. as part of her annual equity award.

Summary

• Heidi Henson, a director at Perspective Therapeutics, Inc. (CATX), filed a Form 4 on March 5, 2025, reporting a transaction.
• On March 3, 2025, Henson acquired 50,000 stock options with an exercise price of $2.46.
• These options represent her annual equity award for 2025, approved by the Issuer's Board of Directors on February 12, 2025.
• The options vest in full on March 3, 2026, contingent upon Henson's continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a standard practice.

Positives

• The grant of stock options to a director aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of one year is fairly standard, incentivizing continued service.
• The size of the grant (50,000 options) would need to be compared to grants made to directors at similarly sized biotech companies to assess its relative magnitude.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates